Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BGB149 (Tilvestamab) in Healthy Volunteers
NCT03795142Phase 1Completed
- Sponsor
- BerGenBio ASA
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ovarian cancer comparing BGB149 (Tilvestamab) with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent clinical adverse events (AE) at 85 days and Frequency of treatment-emergent laboratory abnormalities at 85 days. Started Dec 2018; status: completed.
02
Drugs
tilvestamab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03795142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795142.